Brought to you by 
BTG gives Vanguard Medica licensing rights to novel therapy
13 Jul 1999
Executive Summary
Vanguard Medica (drug development) received worldwide license and marketing rights from British Technology Group to a novel therapy for elevated blood phosphate levels associated with kidney disease.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BTG gives Vanguard Medica licensing rights to novel therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice